Objectives Parents of children with opsoclonus-myoclonus syndrome (OMS) frequently describe poor sleep and rage attacks. We hypothesized that these manifestations are related and could result from underlying monoaminergic dysfunction.Study design We clinically characterized the sleep and behavioral characteristics of 51 young children with OMS; 19 of those with the most disruptive sleep patterns were treated with trazodone, a soporific serotonergic agent.Results Sleep disturbances, including prolonged sleep latency, fragmented sleep, reduced quantity of sleep, snoring, and nonrestorative sleep, were reported in 32 children, and frequent rage attacks were reported in 25. In 59% of the poor sleepers, parents felt that the problem was severe enough to warrant treatment. Children sleeping <10 hours/night had a higher rage frequency than those who slept more. Of the children who required trazodone, 84% were receiving corticosteroids or adrenocorticotropic hormone (corticotrophin), compared with 37% in the subgroup with normal sleep. Trazodone (3.0 ± 0.4 mg/kg/day) improved sleep and behavior in 95% of the children, significantly increasing total sleep time by 72%, decreasing the number of awakenings by 76%, and reducing rage attacks by 33%.Conclusions Children with OMS exhibited multiple types of sleep disturbances, which contributed to rage attacks.Trazodone was effective in improving sleep and decreasing rage attacks and was well tolerated, even in toddlers. (J Pediatr 2005;147:372-8) 0 psoclonus-myoclonus syndrome (OMS) is a neuroblastoma-associated paraneoplastic disorder with serious neuropsychiatric sequelae. Of all of the behavioral symptoms of OMS, such as cognitive impairment, attention deficit disorder (ADD), and obsessive-compulsive disorder, sleep disturbance and rage attacks are the most difficult for the family to cope with. 1 Reduced quality of sleep can also harm the developing child by impairing emotional development, learning, and growth. 2 Multiple pharmacologic interventions have been unsuccessful in children with OMS, because of a lack of efficacy or the propensity for paradoxical reactions to sedatives in this disorder. 3Trazodone hydrochloride, a sedating triazolopyridine derivative with some anxiolytic and hypnotic properties, was first marketed in the United States as an antidepressant in 1983. It is principally a serotonergic agent. 4 In adults, the antidepressant effect occurs at doses of 300 to 600 mg, but in sub-antidepressant doses (50 to 100 mg), it also treats depression-associated sleep disorders. 5 Although understudied in children under 12 years old, it is used in older children to treat migraine headaches, disruptive behavior, depression,8 and sleep disorders. 9We hypothesized a perturbation of monoaminergic neurotransmission to account for sleep disturbances and rage attacks in OMS. Abnormalities of cerebrospinal fluid (CSF) monoamine metabolites have been found in OMS 10 and in disruptive behavioral disorders of children and adolescents." Trazodone, with its serotonergic pro...